Medacta Group Ltd

MOVE

Equity

ISIN CH0468525222 / Valor 46852522

SIX Swiss Exchange (2024-11-22)

CHF 110.80+2.21%

Medacta Group Ltd
UMushroom community rating:

5.00 1 votes No rating yet

NegativeNeutralPositive

About company

Medacta Group Ltd is a Swiss-based company specializing in the development, manufacture, and sale of orthopaedic products and surgical techniques. Founded in 1999 by Dr. Alberto Siccardi, the company has focused on innovation in the field of orthopaedics, including minimally invasive surgery (MIS) and personalized medicine solutions. Medacta has expanded its product range to include knee, hip, and spine implants, as well as computer-assisted surgery systems. The company also emphasizes medical education through its M.O.R.E. (Medacta Orthopaedic Research and Education) Institute, which supports the dissemination of its surgical techniques. In 2019, Medacta celebrated its 20th anniversary by becoming a publicly listed company on the SIX Swiss Exchange. Over the years, Medacta has grown internationally, establishing subsidiaries and expanding its market presence across Europe, the United States, Asia, and Australia.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the fourth quarter of 2023, Medacta Group Ltd reported a significant revenue increase of 19.5% at constant currency, reaching EUR 510.8 million. This growth was driven by strong performance across all business sectors and regions, with notable contributions from new customer acquisitions worldwide.

Gross Profit

Medacta Group Ltd's gross profit for Q4 2023 grew to EUR 347.8 million, up from EUR 305.3 million in the previous year. The gross profit margin was 68.1%, slightly down from 69.8% in 2022, primarily due to currency impacts and geographic mix effects.

Adjusted EBITDA

Adjusted EBITDA for Medacta Group Ltd in Q4 2023 increased to EUR 134.2 million, compared to EUR 120.4 million in 2022. This corresponds to a margin of 27.9% at constant currency, or 26.3% reported, reflecting effective cost management and leveraging on fixed costs despite negative FX effects and inflationary pressures.

Adjusted EBIT

Medacta Group Ltd's adjusted EBIT for Q4 2023 rose to EUR 75.7 million, representing 14.8% of revenues, up from EUR 68.9 million, or 15.8% of revenues, in 2022. The change in EBIT margin was influenced by the decrease in EBITDA, partially offset by leverage on depreciation and amortization.

Dividend Proposal

The Board of Directors of Medacta Group Ltd has proposed a distribution of CHF 0.55 per share for the fiscal year 2023, up from CHF 0.54 in 2022. This proposal reflects the company's strong financial performance and commitment to returning value to shareholders.

Summarized from source with an LLMView Source

Key figures

-5.62%1Y

-20.3%3Y

38.7%5Y

Performance

25.0%1Y

33.1%3Y

37.5%5Y

Volatility